Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

New assay simultaneously visualize gene number, protein expression in individual cells

Researchers have discovered a method for simultaneously visualizing gene number and protein expression in individual cells. The fluorescence microscopy technique could permit a detailed analysis of the relationship between gene status and expression of the corresponding protein in cells and tissues, and bring a clearer understanding of cancer and other complex diseases, according to researchers who led the study

23 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

Cancer Research UK's Drug Development Office has opened a trial of a new combination of drugs for the treatment of patients with brain cancer.

7 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

First report of alternative lengthening of telomeres in human cancer subtypes

The first report of the presence of alternative lengthening of telomeres (ALT) in cancers arising from the bladder, cervix, endometrium, esophagus, gallbladder, liver, and lung was published today in The American Journal of Pathology. The presence of ALT in carcinomas can be used as a diagnostic marker and has implications for the development of anti-cancer drug therapies.

3 Sep 2011

Valproic acid may increase survival for brain tumor patients

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures.

2 Sep 2011

New imaging device enables scientists to see tumor cells traveling in the brain

For the first time, scientists can see pathways to stop a deadly brain cancer in its tracks. Researchers at Case Western Reserve University School of Medicine have imaged individual cancer cells and the routes they travel as the tumor spreads.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

Patients suffering from an aggressive brain cancer will benefit from the results of a University of Illinois study that could advance the development of targeted gene therapies and improve prognosis.

23 Aug 2011

Wistar Institute, Graham Cancer Center enter research collaboration

Christiana Care Health System's Helen F. Graham Cancer Center and The Wistar Institute, an international leader in biomedical research, have entered into an historic partnership to collaborate on translational cancer research with the aim of bringing the latest discoveries in cancer research to cancer patients in the community.

20 Aug 2011

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.

5 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company's lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.

27 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

In a unique study, researchers at The Long Island Brain Tumor Center at Neurological Surgery, P.C. are examining whether hyperbaric oxygen therapy - breathing pure oxygen while in a pressurized chamber - may prove a useful addition to the current standard of care for patients newly diagnosed with glioblastoma, an aggressive brain cancer.

22 Jul 2011

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.

22 Jul 2011

Glioblastoma News and Research

Further Reading

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

New assay simultaneously visualize gene number, protein expression in individual cells

USPTO issues patent for Lixte's LB-100 to treat cancer

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

First report of alternative lengthening of telomeres in human cancer subtypes

Valproic acid may increase survival for brain tumor patients

New imaging device enables scientists to see tumor cells traveling in the brain

MDxHealth first half 2011 commercial revenues increase 19%

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

Wistar Institute, Graham Cancer Center enter research collaboration

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

Celldex second quarter net loss increases to $10.2 million

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News